Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
NAD+ metabolism and the control of energy homeostasis
Houtkooper RH, et al. Endocr Rev. 2010. PMID 19149596.
MK-677 in healthy older adults
Nass R, et al. Annals of Internal Medicine. 2008. PMID 18981485.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical perspective. 2006. PMID 18046908.
Bremelanotide in premenopausal women with sexual arousal disorder
Randomized controlled trial. 2006. PMID 16839319.
Effects of topical copper tripeptide complex on laser-resurfaced skin
Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.
Delta sleep-inducing peptide: a still unresolved riddle
Graf MV, Kastin AJ. Peptides. 2006. PMID 16539679.
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
Pulsatile GH secretion persists during CJC-1295 stimulation
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
LL-37 ocular-surface expression and antimicrobial activity
Gordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
Antiepileptic activity of DSIP and its analogue in rats
Preclinical study. 2005. PMID 15911358.
Effects of benzyl alcohol on protein aggregation
Zhang Y, et al. Journal of Pharmaceutical Sciences. 2005. PMID 15614819.
Pralmorelin: GHRP-2 drug profile
AdisInsight profile. 2004. PMID 15230633.
AOD-9604 development review
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Subcutaneous hMG in controlled ovarian stimulation
Clinical study. 2000. PMID 10871458.
DSIP effects on rat EEG and power spectra
Primary 2000 Wistar-rat study; PMID 11214497.
Action of long(R3)-IGF-1 on protein metabolism in beef heifers
Animal study. 1999. PMID 10370861.
Growth hormone-releasing peptides
Ghigo E, et al. 1997. PMID 9186261.
Human pigmentation and pharmacokinetics of a synthetic melanotropin
Human study. 1997. PMID 9113347.
The dermorphin peptide family
Review. 1996. PMID 8981054.
GHRP-6 response in hypothalamopituitary disconnection
Human endocrine study. 1995. PMID 7883854.
Potent long-acting GRF analogues
Rivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
GRF1-29 compared with longer human GRF fragments
Losa M, et al. Klin Wochenschr. 1984. PMID 6240568.
Human growth hormone
Foundational review. 1968. PMID 4914846.
Certain Bulk Drug Substances That May Present Significant Safety Risks
U.S. FDA. Current compounding safety-information page.
ZEPBOUND (tirzepatide) prescribing information
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Falutz J, et al. Journal of Acquired Immune Deficiency Syndromes. PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff
SYNCHRONIZE-1 trial registry
ClinicalTrials.gov NCT06066515.
A Study of Retatrutide in Participants Who Have Obesity or Overweight
ClinicalTrials.gov record NCT04881760.
VYLEESI (bremelanotide) prescribing information
DailyMed/FDA label.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
